Latest News

  • VIB moves forward in the development of a COVID-19 prophylactic
    Earlier this year, the lab of Xavier Saelens (VIB-UGent) announced the discovery of a unique single-domain antibody (VHH) that is capable of binding the SARS-CoV-2 Spike protein of the COVID-19 virus. This antibody was developed in collaboration with two research groups in the US. The team has now established that Fc fusions of the VHH can neutralize pseudotyped SARS-CoV-2, an important step forward in the development of a potential prophylactic drug against the coronavirus. This progress was made possible thanks to the intensive efforts of various teams in the VIB-UGent Center for Medical Biotechnology.
  • Breast screening breakthrough to end unnecessary biopsies
    Harnessing photonics, European scientists have created a new mammographic imaging system that determines benign or malignant breast lesions - spelling an end for unnecessary biopsies and anguish for millions of women.
  • 5 reasons to be optimistic about cancer
    Every nine seconds, there is a new cancer case diagnosed in the EU and it is currently the second leading cause of death following cardiovascular disease. In addition to the considerable impact on the lives of European citizens, cancer puts a huge strain on Europe’s health and social systems as well as the economy.
  • How astronauts will make their own drugs in space
    NASA’s Translational Research Institute for Space Health (TRISH) has funded innovative projects seeking to better protect astronauts' health during deep space missions of three years or more. Two of the six projects focus on ‘just-in-time’ medications, which allow drugs to be manufactured on-demand and on-board the spacecraft – a necessity given that most commercially available medicines have shelf lives of two years or less.
  • Pinpointing rare disease mutations
    New resource that categorises genes essential for supporting life could be used to identify rare disease mutations
view more

Podcasts

view more

Webinars

  • The Promise of Epigenetics in Early Stage Drug Discovery
    Epigenetic targets are exciting to drug discovery scientists because they hold great potential across a wide spectrum of therapeutic areas. The field of epigenetics focuses on the investigation of enzymes that alter gene expression through modification of their target substrates, usually through the addition or removal of methyl or acetyl groups. High-throughput assays to identify agents capable of modifying the action of such enzyme targets has, in the past, proven to be challenging due to the relatively small molecular alterations in addition to the possibility of sequential modifications, leading to multiple end products. As such, high-throughput bioassays that allow the direct, concurrent quantification of multiple modification states are attractive. The RapidFire platform enables high-throughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HPLC, which requires minutes. Moreover, the RapidFire system can be connected to any mass spectrometer providing unparalleled versatility in reaction detection.
  • Integrated Quant / Qual for In-vivo Discovery Bioanalysis using Hybrid Quadrupole-Time-of-Flight Mass Spectrometry
    Ultra high performance liquid chromatography (UHPLC) coupled with orthogonal acceleration hybrid quadrupole-time-of-flight (QqTOF) mass spectrometry is an emerging technique offering new strategies for the efficient screening of new chemical entities (NCE) and related molecules at the early discovery stage within the pharmaceutical industry.
  • Drug Delivery: enabling technology for discovery and development
    The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
  • Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
    AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
view more

Features

view more

Downloads

view more

25 Hottest Articles

view more